NLS Global report

Pfizer and Valneva's Lyme disease vaccine candidate demonstrated strong efficacy in their Phase 3 VALOR trial.

A global investigation led by journalists from the International Consortium of Investigative Journalists shows how Merck & Co has deployed a range of strategies to sustain high prices and stifle competition.

MSD and Terns Pharmaceuticals have entered into a definitive agreement under which MSD, through a subsidiary, will acquire Terns for an approximate equity value of USD 6.7 billion.

The Belgian region of Flanders has long been one of Europe’s most industrially dynamic regions. Its economy is anchored by advanced manufacturing, logistics, and a life science sector that consistently performs far above the region’s size.

Centessa is advancing a pipeline of orexin receptor 2 (OX2R) agonists designed to address the neurobiological system critical to the sleep-wake cycle to treat excessive daytime sleepiness and disorders of impaired wakefulness.

The two companies have entered into a definitive agreement under which Biogen has agreed to acquire all outstanding shares of Apellis for USD 41.00 per share in cash at closing, or approximately USD 5.6 billion.